Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Mental Disease

PUBLISHER: Grand View Research | PRODUCT CODE: 1553654

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1553654

Bipolar Disorder Market Size, Share & Trends Analysis Report By Type (Mood Stabilizer, Anticonvulsants, Antipsychotic Drugs), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

Bipolar Disorder Market Growth & Trends:

The global bipolar disorder market is anticipated to reach USD 5.87 billion by 2030, growing at a CAGR of 2.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Government support for generating awareness about the bipolar disorder and technological advancements that facilitate accurate detection of a patient's mood and mental state are a few of the factors driving the growth of this market.

The rising prevalence of bipolar disorders is likely to propel market growth in the forecast period. Government initiatives also drive the market growth. For instance, International Bipolar Foundation's Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) are programs offered by the Social Security Administration (U.S.) for the benefit of the people affected by bipolar disorder.

Besides, technological advancements in smartphones, smartwatches, and wearable devices improve diagnosis rates by capturing physiological, behavioral, and environmental data effectively to detect the patient's mood and mental state. Online self-management tools also result in timely intervention, thereby improving diagnosis rates and treatment rates for the disorder. However, the patent expiry of blockbuster drugs in this market is likely to impact market dynamics in the forecast period. Additionally, the drugs in the bipolar disorder market are bound to face intense competition from generic drugs, as treatment options for bipolar disorder. Other factors likely to restrain market growth in the forecast period include side effects associated with bipolar drugs, and misdiagnosis of bipolar disorder.

Bipolar Disorder Market Report Highlights:

  • The mood stabilizer segment dominated the market in 2023, with a share of 35.0% in 2023 due to the rising prevalence of bipolar disorder.
  • The selective serotonin reuptake inhibitor segment dominated the market in 2023, with a share of 25.0%. The factors responsible for the market growth are the efficacy and safety profile of selective serotonin reuptake inhibitors (SSRIs), which are effective in managing the depressive symptoms occurring due to bipolar disorder.
  • The hospital pharmacies segment dominated the market in 2023, with a share of 49.8% in 2023. This market growth was attributed to the increase in the number of patients seeking a diagnosis of their mental health.
  • North America dominated the bipolar disorder market with a market share of 39.4% in 2023. This was attributed to the increase in the cases of bipolar disorders and the presence of significant medical institutes in the region.
Show more
Product Code: GVR-2-68038-033-0

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Bipolar Disorder Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Bipolar Disorder Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Bipolar Disorder Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Bipolar Disorder Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Mood Stabilizer
    • 4.3.1. Mood Stabilizer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Anticonvulsants
    • 4.4.1. Anticonvulsant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Antipsychotic Drugs
    • 4.5.1. Antipsychotic Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Antidepressant Drugs
    • 4.6.1. Antidepressant Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Antianxiety Drugs
    • 4.7.1. Antianxiety Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Other Types
    • 4.8.1. Other Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Bipolar Disorder Market: Drug Class Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Bipolar Disorder Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Selective Serotonin Reuptake Inhibitor
    • 5.3.1. Selective Serotonin Reuptake Inhibitor Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Serotonin Norepinephrine Reuptake Inhibitor
    • 5.4.1. Serotonin Norepinephrine Reuptake Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Tricyclic Antidepressant Drugs
    • 5.5.1. Tricyclic Antidepressant Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Monoamine Oxidase Inhibitors
    • 5.6.1. Monoamine Oxidase Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Benzodiazepines
    • 5.7.1. Benzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Beta Blockers
    • 5.8.1. Beta Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Other Drugs Classes
    • 5.9.1. Other Drugs Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Bipolar Disorder Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Bipolar Disorder Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Bipolar Disorder Market: Regional Estimates & Trend Analysis

  • 7.1. Bipolar Disorder Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Advanced Micro Devices
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. AstraZeneca
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Eli Lilly and Company
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. GSK plc
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Johnson & Johnson Services, Inc
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Pfizer Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. AbbVie Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Otsuka Holdings Co., Ltd.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Bristol-Myers Squibb Company
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Teva Pharmaceutical Industries Ltd.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Sumitomo Pharma America, Inc
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!